Analyst Price Targets — KLRS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 10:55 am | — | Wedbush | $17.00 | $4.83 | TheFly | Kalaris Therapeutics initiated with an Outperform at Wedbush |
| April 16, 2026 8:54 am | — | Morgan Stanley | $14.00 | $5.87 | TheFly | Kalaris Therapeutics initiated with an Overweight at Morgan Stanley |
| March 9, 2026 2:57 pm | Chris Raymond | Raymond James | $23.00 | $9.51 | StreetInsider | Raymond James Reiterates Strong Buy Rating on Kalaris (KLRS) |
| December 23, 2025 9:31 am | — | Chardan Capital | $19.00 | $10.06 | TheFly | Kalaris Therapeutics initiated with a Buy at Chardan |
| July 23, 2025 8:52 am | Biren Amin | Piper Sandler | $3.00 | $2.57 | TheFly | Kalaris Therapeutics assumed with a Neutral at Piper Sandler |
Latest News for KLRS
BERKELEY HEIGHTS, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate in a Fireside Chat at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference. Kalaris is currently…
Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027 Potential Phase 3 clinical trials remain on track for initiation by year-end 2027 $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026 is expected to fund operations into the fourth quarter of 2027 and through key clinical milestones BERKELEY HEIGHTS, N.J., Aug. 11, 2026 (GLOBE…
Kalaris Therapeutics Inc. (NASDAQ: KLRS - Get Free Report)'s stock price rose 15.4% during mid-day trading on Monday. The company traded as high as $4.09 and last traded at $4.05. Approximately 155,903 shares changed hands during mid-day trading, a decline of 76% from the average daily volume of 653,556 shares. The stock had previously closed
Abbott Cooper PLLC is investigating fiduciary duty claims for Kalaris Therapeutics (formerly AlloVir) holders who owned shares before November 7, 2024.
Strategic finance leader with over 20+ years of experience in the biotechnology space CFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study of TH103 in treatment naïve nAMD patients BERKELEY HEIGHTS, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KLRS.
U.S. House Trading
No House trades found for KLRS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.